Clinical value of edaravone combined with ultra-early small bone window craniotomy in the treatment of hypertensive cerebral hemorrhage
Objective To analyze the effect of edaravone combined with ultra-early small bone window craniotomy in the treatment of hypertensive intracerebral hemorrhage(HICH).Methods 84 patients with HICH in a hospital from January 2023 to December 2023 were selected as the research objects and divided into two groups according to the difference of treatment plan.The control group(41 cases)was treated with ultra-early small bone window craniotomy,and the edaravone group(43 cases)was treated with edaravone on the basis of the control group.The therapeutic effect,cerebrovascular function parameters[systemic vascular resistance(SVR),mean cerebrovascular blood flow(Qmean),dynamic resistance(DR)],neurological function[ational institutes of health stroke scale(NIHSS)score,neuronal specific enolase(NSE),glial fibrillary acidic protein(GFAP),myelin basic protein(MBP)]and the incidence of complications were compared between the two groups.Results Compared with the control group(65.85%),the total effective rate of the edaravone group(86.05%)was higher(P＜0.05).After treatment,SVR and DR of the edaravone group were lower than those of the control group,and the Qmean was higher than that of the control group(P＜0.05).After treatment,neurological function was improved in both groups,and NIHSS score and the levels of serum NSE,GFAP and MBP in edaravone group were all lower than those in the control group(P＜0.05).The total incidence of complication rate of edaravone group(9.30%)was lower than that of the control group(29.27%)(P＜0.05).Conclusion Edalavone combined with ultra-early small bone window craniotomy is effective in the treatment of HICH,which can effectively improve cerebrovascular function and neurological function,and with high safety.
EdaravoneSmall bone window craniotomyUltra-earlyHypertensive cerebral hemorrhageNeurological functionCerebrovascular function
NETL
NSTL
万方数据
